Amloten® 25: Each tablet contains Amlodipine Besilate BP equivalent to Amlodipine 5 mg and Atenolol BP 25 mg.
Amloten® 50: Each tablet contains Amlodipine Besilate BP equivalent to Amlodipine 5 mg and Atenolol BP 50 mg.
Amloten® is a fixed-dose combination of amlodipine and atenolol. Amlodipine is a calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle; it has a greater effect on vascular smooth muscle cells than on cardiac muscle cells. It is a peripheral vasodilator, acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.
Atenolol is a selective β1 blocker. Atenolol causes a reduction in blood pressure by lowering cardiac output, decreasing the plasma renin activity and sympathetic outflow from CNS. Atenolol also causes a reduction in myocardial oxygen demand by virtue of its negative inotropic and negative chronotropic effects.
Amloten® is indicated for the treatment of hypertension and chronic stable angina.
The recommended dosage is one tablet of Amloten® 25 or Amloten® 50 daily. If necessary, the dosage may be increased to two tablets daily. The dosage, however, should be individualized.
OR AS DIRECTED BY THE PHYSICIAN.
Disopyramide: Atenolol reduces the clearance of disopyramide by 20%. Additive negative inotropic effects on the heart may be produced. Ampicillin at doses of 1 g and above may reduce atenolol levels. Oral antidiabetic and insulin: Beta-blockers may decrease tissue sensitivity to insulin and inhibit insulin secretion e.g. in response to oral antidiabetics. Atenolol has less potential for these actions.
Overdosage:
Though not documented, hypotension and less frequently congestive cardiac failure may occur in cases of overdosage. Unabsorbed drugs may be removed by gastric lavage or administration of activated charcoal. Symptomatic treatment is suggested.
Bronchospasm: The combination should be used with caution in patients with airway obstruction.
Renal Impairment: The combination can be used in patients with renal impairment. However, caution may be necessary if the creatinine clearance is less than 30 mL/min.
Hepatic Impairment: Caution may be necessary in the use of the combination in patients with severe liver damage because of prolongation of the elimination half-life of amlodipine.
Drug Withdrawal: Since coronary heart disease may exist without being recognized, patients should be warned against stopping the drug suddenly. Any discontinuation should be gradual and under observation.
Hypotension: Excessive fall of blood pressure can occur in some patients especially the elderly.
Store in a cool and dry place protected from light. Keep all medicines out of reach of children.